EN

What the GLP‑1 trials found

Pick a medicine sold in the UAE and a dose to see its main trial as the label, or the trial paper, reports it: average weight change, how many people reached 5, 10, 15 or 20%, and the side effects and stopping rates beside them.

Nothing you enter leaves your device Every number cites its source section
Trial averages, not a prediction for you. This doesn't replace the leaflet or your doctor. Some people lose much more than the average and some lose very little. Talk to your doctor before starting, stopping or changing a medicine.Information only, not a promotion. Every medicine named here is prescription-only. Only a doctor can decide whether one is right for you and prescribe it. We don't recommend, rank or favour any medicine. Where we list several, they're in alphabetical order. We don't sell medicines or take money from drug companies.

Pick a medicine and dose

Medicine
kg

Shows what the trial's averages and proportions would mean in kilograms. Not a prediction.

How these trials work
  • People were put into groups by chance: one got the medicine, one got a placebo (a dummy injection or dummy pill with no medicine in it).
  • Both groups got the same diet and activity advice.
  • The gap between the two groups is what the medicine added.
These trials can't be compared or ranked against each other. They had different people, lengths, doses and diet advice, ran at different times, and their results are reported in different ways. Only a head-to-head trial tests two medicines in the same trial: see Compare.

Private by design: worked out in your browser. Nothing is sent or stored, and nothing goes in the link. Privacy notice

How this works

UAE leaflets aren't published online, so for each medicine we use the closest public text: its European (EU) label from the European Medicines Agency. Trial results come from section 5.1 and side effects from section 4.8, which often pools several trials; the card says which. Where the label doesn't give a number for that trial alone, we use the published trial paper and say so. Where neither gives a number, we leave it out. Every number sits in one data block on this page with its source.

"Average" weight change is the mean for the whole group. The share who reached at least 5, 10, 15 or 20% shows the spread: it's a range, not one number. If you enter your weight, we multiply it by the same percentages. That's arithmetic on trial averages, not a forecast.

Ozempic and Rybelsus are approved for type 2 diabetes, not weight loss, and Mounjaro also has a diabetes trial. Their labels report the average weight change in these diabetes trials in kilograms, so we show that. Only the Mounjaro label also gives how many people lost 5, 10 or 15% of their weight, so only that card shows it.

Foundayo is approved in the UAE but has no public UAE or EU label, so its card uses the trial paper's summary.9,10 Wegovy's 7.2 mg dose isn't approved in the UAE, so its trial isn't shown.11

What this can't tell you

  • How much you will lose. Your result depends on you, your dose and how long you take it, and isn't predicted by a trial average.
  • Which medicine works more. Separate trials can't be ranked.
  • What happens after stopping. Weight usually comes back in part: see Stopping and the long term.
  • Rare or long-term risks. Those are in each label's warnings, and in Side effects and risks.

Questions people ask

Can I compare the numbers for different medicines?

No. Each trial had different people, lengths, doses and diet advice, so the numbers can't be compared or ranked against each other. Only a head-to-head trial, where both medicines are tested in the same trial, can compare them.

Is this how much weight I will lose?

No. These are trial averages, not a prediction for you. In every trial some people lost much more than the average and some lost very little. That's why the tool shows how many people reached each amount, not one number.

What is a placebo?

A dummy injection or dummy pill with no medicine in it. In these trials people were put into groups by chance, and both groups got the same diet and activity advice. The gap between the medicine group and the dummy group is what the medicine added.

Why do the numbers come from European labels?

UAE leaflets aren't published online. The European labels are the closest public official text, so we use them and name the section. The leaflet in your own pack is the one that applies to you.

Is anything I enter saved or sent?

No. The weight you enter is used only in your browser to turn the trial percentages into kilograms. Nothing is sent or stored.

Sources

  1. Wegovy (semaglutide) injection and Wegovy tablets, EU product information, Novo Nordisk, European Medicines Agency, file dated 13 Aug 2026. Injection: section 5.1 (Table 4: STEP 1) and 4.8 (gastrointestinal side effects, STEP 1 to 4 pooled); tablets: section 5.1 (Table 2: OASIS 4) and 4.8 (gastrointestinal side effects in OASIS 4). The EU label, used because UAE leaflets aren't published online; not the UAE label. EMA PDF. Checked 14 Oct 2026.
  2. Mounjaro (tirzepatide) injection, EU product information, Eli Lilly, European Medicines Agency, file dated 6 Aug 2026. Section 5.1 (Table 8: SURMOUNT-1; Table 2: SURPASS-1, on-treatment results) and 4.8 (gastrointestinal side effects). The EU label, not the UAE label. EMA PDF. Checked 14 Oct 2026.
  3. Saxenda (liraglutide) injection, EU product information, Novo Nordisk, European Medicines Agency, file dated 10 Jul 2025. Section 5.1 (Table 5: Trial 1 = SCALE Obesity and Pre-Diabetes, week 56) and 4.8 (side effects). The EU label, not the UAE label. EMA PDF. Checked 14 Oct 2026.
  4. Ozempic (semaglutide) injection, EU product information, Novo Nordisk, European Medicines Agency, file dated 20 Jul 2026. Section 5.1 (Table 2: SUSTAIN 1) and 4.8 (gastrointestinal side effects). The EU label, not the UAE label. EMA PDF. Checked 14 Oct 2026.
  5. Rybelsus (semaglutide) 3, 7 and 14 mg tablets, EU product information, Novo Nordisk, European Medicines Agency, file dated 20 Apr 2026. Section 5.1 (Table 2: PIONEER 1) and 4.8 (gastrointestinal side effects). The EU label, not the UAE label. EMA PDF. Checked 14 Oct 2026.
  6. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. PMID 33567185. Abstract: stopped because of gastrointestinal events 4.5% vs 0.8%. Funded by Novo Nordisk. PubMed. Checked 14 Oct 2026.
  7. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. PMID 35658024. Abstract: stopped because of adverse events 4.3%, 7.1%, 6.2% and 2.6%; main analysis −15.0%, −19.5%, −20.9% and −3.1%. Funded by Eli Lilly. PubMed. Checked 14 Oct 2026.
  8. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity and Prediabetes). N Engl J Med 2015;373:11-22. PMID 26132939. Abstract: serious events 6.2% vs 5.0%. Funded by Novo Nordisk. PubMed. Checked 14 Oct 2026.
  9. Wharton S et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med 2025;393:1796-1806. PMID 40960239. Abstract: doses 6, 12 and 36 mg; mean change −7.5%, −8.4%, −11.2% vs −2.1%; 36 mg: 54.6%, 36.0% and 18.4% reached 10, 15 and 20% vs 12.9%, 5.9% and 2.8%; stopped because of adverse events 5.3 to 10.3% vs 2.7%. Funded by Eli Lilly. PubMed. Checked 14 Oct 2026.
  10. Khaleej Times. Foundayo obesity pill approved in the UAE: prescription, eligibility and availability, 17 April 2026. khaleejtimes.com. Checked 14 Oct 2026.
  11. Gulf News. Higher maintenance dose of weight-loss drug Wegovy approved in EU: when will UAE get it? ("discussions with UAE regulators are ongoing, though no timeline has been set"), 2 March 2026. gulfnews.com. Checked 14 Oct 2026.

Last checked 14 Oct 2026 · Next review due Jan 2027

How this tool was made. Written by the GLP Guidebook team from the EU labels and trial papers above, each opened and checked. The trials were paid for by the makers of the medicines (Novo Nordisk or Eli Lilly). It's general information, not medical advice, and it doesn't replace the leaflet in your pack or your doctor. Talk to a licensed doctor before starting, stopping or changing any medicine. In an emergency, call 998 for an ambulance, or 999. How we write